[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-marrow-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-marrow-transplant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100498858","phase-2-shingrix-in-recipients-of-allogeneic-transplants-100498858",false,"NCT05775718","Shingrix In Recipients of Allogeneic Transplants","Safety and Immunogenicity of Shingrix Administered to Recipients of Allogeneic Peripheral and Cord Blood Stem Cell Transplants: Effect of Timing of Vaccination After Transplantation","Allo","Inclusion Criteria:\n\n* Allo-SCT recipients being age 18 - 79 years at time of allo-SCT.\n* Written informed consent being obtained from the subject\n* Two doses of RZV, separated by 2 to 6 months, administered at least 1 year after allo-SCT.\n* Enrollment at \\>\u002F= 18 months after second dose of Shingrix.\n* Female subjects of childbearing potential (FOCBP) enrolled in the study only if they:\n\n  * have practiced adequate contraception for 30 days prior to vaccination with any dose of zoster vaccine and\n  * have a negative pregnancy test on the day of each dose of zoster vaccine and\n  * agree to continue adequate contraception during the vaccination period and for 2 months after receipt of the vaccine.\n* Investigator belief that the participant will comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* Active Graft Versus Host Disease (aGVHD) at the time of enrollment and receipt of the third dose of RZV\n* Having received ≥20 mg prednisone for more than 2 weeks (or equivalent) in the 8 weeks preceding enrollment.\n* Receiving any significant immunosuppressive therapy other than for graft maintenance, in the opinion of the investigator.\n* Having received a live attenuated vaccine within the last 4 weeks, or inactivated vaccine in the last 2 weeks, prior to enrollment.\n* Having a history of HZ after the administration of the primary 2-dose RZV immunization regimen.\n* Pregnancy or breastfeeding\n* Receiving investigational drugs from 30 day before enrollment or planned during the study\n* Inability of participants unable to comply with the study schedule in the opinion of the investigator","ALL","18 Years","79 Years",{"count":21,"type":22},55,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.",[28,29],"Bone Marrow Transplant","Stem Cell Transplant","RECRUITING","2026-02-02",{"date":33,"type":34},"2026-02-05","ACTUAL",{"date":36,"type":34},"2023-10-24",{"date":38,"type":22},"2030-12-01",{"name":40,"class":41},"University of Colorado, Denver","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100371351","activity-levels-in-bone-marrow-transplant-patients-100371351","NCT04115241","Activity Levels in Bone Marrow Transplant Patients","Patients who will be receiving a bone marrow transplant are eligible for this study","99 Years",{"count":51,"type":22},200,"OBSERVATIONAL","Participants in this study will be receiving a bone marrow transplant. This study is designed to evaluate correlations between activity levels and length of stay, quality of life, and hand grip strength.",[28],[56,57,58,59],"leukemia","multiple myeloma","myelodysplastic syndrome","stem cell transplant","2025-11-05",{"date":62,"type":34},"2025-11-10",{"date":64,"type":34},"2019-05-23",{"date":66,"type":22},"2030-05-23",{"name":68,"class":41},"Michael Tomasson",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":80,"conditions":81,"keywords":106,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":79,"type":22},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[82,83,84,85,86,87,88,89,90,91,28,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Kidney Transplant","Familial Hypercholesterolaemia","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Cancer (Solid Tumors)","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[107,108,109],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":112,"type":34},"2025-08-08",{"date":114,"type":34},"2025-04-01",{"date":116,"type":22},"2029-01-31",{"name":118,"class":41},"Semmelweis University",3,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":119},"100589944","mosaic-trial-for-stem-cell-transplant-recipients-100589944","NCT06960993","Mosaic Trial for Stem Cell Transplant Recipients","Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients","Mosaic","Inclusion Criteria:\n\n* Diagnosed with a hematologic cancer according to medical records\n* Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites\n* Aged 18 or older (no upper limit)\n* English or Spanish Proficient\n* Interested in using a website to learn about stem cell transplant\n* Ability to understand and willingness to sign an informed consent document and comply with all study procedures\n\nExclusion Criteria:\n\n* Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms\n* Undergoing the first in a planned tandem stem cell transplant\n* Unable to provide meaningful consent (severe cognitive impairment or language difficulties)",{"count":129,"type":22},356,[131],"NA","The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups).\n\nThe main questions this trial aims to answer are:\n\n1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life?\n2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and\u002For reductions in avoidant coping and perceived stress?\n3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English\u002FSpanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.",[134,29,28,93,94,135,136],"Hematologic Malignancy","Multiple Myeloma","Myelodysplastic Syndromes","2025-07-17",{"date":139,"type":34},"2025-07-18",{"date":141,"type":34},"2025-04-28",{"date":143,"type":22},"2030-02-01",{"name":145,"class":41},"Northwestern University"]